Learn More
OBJECTIVES This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in(More)
BACKGROUND Post-infectious irritable bowel syndrome is a common clinical phenomenon of uncertain aetiology. AIM To test the association between intestinal permeability and irritable bowel syndrome(More)